Contract 75A50126F61013
Seqirus Inc · Department Of Health And Human Services · April 3, 2026
Seqirus Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on April 3, 2026 for $450,000 of work in biological product (except diagnostic) manufacturing. Performance is in Holly Springs, NC. This is a task or delivery order issued under parent IDIQ 75A50122D00004. It uses firm fixed-price contract pricing.
Contract details
- PIID
- 75A50126F61013
- Parent IDIQ
- 75A50122D00004
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Holly Springs, NC
- First action
- April 3, 2026
Description
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN
Modification timeline
-
April 3, 2026Base award$450.1K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Bio-Rad Laboratories, Inc. | Department Of Health And Human Services | March 31, 2026 | $20.6K |
| Georgia Tech Research Corp | Department Of Health And Human Services | March 28, 2026 | $145.8K |
| Seqirus Inc | Department Of Health And Human Services | March 25, 2026 | $23.7K |
| Seqirus Inc | Department Of Health And Human Services | March 24, 2026 | $0 |
| Battelle Memorial Institute | Department Of Health And Human Services | March 19, 2026 | $2.80M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 19, 2026 | $53.21M |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50126F61013?
Contract 75A50126F61013 is a federal contract awarded to Seqirus Inc by Department Of Health And Human Services on April 3, 2026 for $450,000 of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 0 times since the base award.
Who won contract 75A50126F61013?
Seqirus Inc won contract 75A50126F61013 from Department Of Health And Human Services.
How much is contract 75A50126F61013 worth?
Contract 75A50126F61013 has obligated $450,000 to date.